Análisis opcionales del producto
Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Church & Dwight Co., Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $23.2B | |
|---|---|---|
| Revenue (ttm) | 6.2B | |
| Net income (ttm) | 744.8M | |
| EPS (ttm) | $3.11 | |
| Shares out | 237.2M | |
| P/E (trailing) | 33.6x | |
| P/E (forward) | 23.4x | |
| Dividend | $1.23 (1.17%) | |
| Volume | 1,114,784 | |
| Beta | 0.48 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $5.19B | $5.38B | $5.87B | $6.11B | $6.20B | +4.6% |
| Gross profit | $2.26B | $2.25B | $2.59B | $2.79B | $2.77B | +5.2% |
| Operating income | $1.08B | $597.8M | $1.06B | $807.1M | $1.08B | -0.0% |
| Net income | $827.5M | $413.9M | $755.6M | $585.3M | $736.8M | -2.9% |
| EPS (diluted) | $3.32 | $1.68 | $3.05 | $2.37 | $3.02 | -2.3% |
| EBITDA | $1.31B | $831.9M | $1.06B | $1.09B | $1.30B | -0.1% |
| R&D | $105.2M | $110.0M | $122.4M | $139.7M | $145.6M | +8.5% |
| SG&A | $606.7M | $706.0M | $889.8M | $927.8M | $988.3M | +13.0% |
Recent company headlines from major financial publishers.
The Base scenario reflects the modal operating trajectory. Consumer Domestic anchors consolidated revenue with steady volume compounding in specialty personal care offsetting flattish volume trends in mature laundry categories. Management achieves guided gross margin expansion through continuous productivity and trade optimization, while holding brand marketing at guided levels relative to sales to defend shelf space against scale peer affordability campaigns. Cash flow conversion remains robust, supporting modest annual dividend increases and disciplined bolt-on acquisitions.
Under the Bull scenario, international consumer distribution expands rapidly across Europe and Latin America, while domestic market share gains in TheraBreath and Hero accelerate as household penetration closes the gap toward broader category averages. Manufacturing productivity programs and trade optimization deliver gross margin expansion surpassing guidance, lifting operating margins beyond historical averages and driving superior free cash flow compounding.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 6.7% | $88.1 | $91.2 | $94.6 | $98.5 | $103 |
| 7.2% | $81.6 | $84.0 | $86.7 | $89.7 | $93.1 |
| 7.7% | $76.2 | $78.2 | $80.3 | $82.7 | $85.3 |
| 8.2% | $71.7 | $73.3 | $75.0 | $76.9 | $79.1 |
| 8.7% | $67.8 | $69.1 | $70.6 | $72.2 | $73.9 |
Upcoming earnings date and setup when available.
La calificación que llevaba la edición de análisis publicada cada mes. Una calificación compara el precio en la fecha del análisis con el valor razonable; no es un registro de si la valoración acertó.
| Año | ene | feb | mar | abr | may | jun | jul | ago | sept | oct | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |